Literature DB >> 28739419

Retinal Nonperfusion in the Posterior Pole Is Associated With Increased Risk of Neovascularization in Central Retinal Vein Occlusion.

Luke Nicholson1, Clara Vazquez-Alfageme1, Namritha V Patrao1, Ioanna Triantafyllopolou1, James W Bainbridge1, Philip G Hykin1, Sobha Sivaprasad2.   

Abstract

PURPOSE: To review the definition of ischaemic central retinal vein occlusion (CRVO) and stratify the risk of neovascular complication based on wider areas of visible retinal non-perfusion.
DESIGN: Retrospective consecutive case series and image analysis study.
METHODS: Setting: Moorfields Eye Hospital, London, United Kingdom. STUDY POPULATION: Forty-two consecutive treatment-naïve eyes with CRVO imaged with ultra-widefield angiography with a minimum of 12 months follow-up. OBSERVATION PROCEDURE: The spatial location and total area of retinal nonperfusion (measured in disc areas, DA) were determined using the validated concentric rings method. The area was corrected for projection distortion. The images were graded by 2 retinal physicians and average measurements used. MAIN OUTCOME MEASURES: Development of neovascular complications.
RESULTS: The percentage of eyes developing new vessels increased from none in eyes with less than 10 DA of nonperfusion in total to 14.3% in eyes with 10-30 DA, 20.0% for 30-75 DA, and 80% risk with 75-150 DA of nonperfusion. From 13 (31.0%) eyes with a perfused posterior pole (an area encompassing a 5 disc diameter radius centered at the fovea) and more than 10 DA of nonperfusion isolated in the periphery (beyond the posterior pole), only 1 (7.7%) eye developed new vessels, odds ratio (OR) 0.12 [95% confidence interval (CI): 0.01, 1.03]. Comparatively, for 13 (31.0%) eyes with more than 10 DA of nonperfusion in the posterior pole, 11 (84.6%) developed new vessels, OR 74.25 [95% CI: 9.26, 595.30], P < .001.
CONCLUSION: With ultra-widefield angiography, we have ascertained that posterior pole nonperfusion of more than 10 DA remains the key risk factor for new vessel development compared to areas of nonperfusion confined to the periphery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 28739419     DOI: 10.1016/j.ajo.2017.07.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

Review 1.  Review: The Development of Risk Factors and Cytokines in Retinal Vein Occlusion.

Authors:  Yi Tang; Yan Cheng; Shuo Wang; Yongjie Wang; Pengjia Liu; Hong Wu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

2.  Retinal vein occlusion (RVO) guideline: executive summary.

Authors:  Luke Nicholson; Stephen J Talks; Winfried Amoaku; Katherine Talks; Sobha Sivaprasad
Journal:  Eye (Lond)       Date:  2022-03-17       Impact factor: 4.456

3.  Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

Authors:  Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier
Journal:  Health Technol Assess       Date:  2021-06       Impact factor: 4.014

4.  Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy.

Authors:  Luke Nicholson; Jayashree Ramu; Errol W Chan; James W Bainbridge; Philip G Hykin; Stephen J Talks; Sobha Sivaprasad
Journal:  JAMA Ophthalmol       Date:  2019-06-01       Impact factor: 7.389

5.  The clinical relevance of ultra-widefield angiography findings in patients with central retinal vein occlusion and macular oedema receiving anti-VEGF therapy.

Authors:  Luke Nicholson; Clara Vazquez-Alfageme; Piyali Sen; Namritha V Patrao; Tunde Peto; Yit Yang; Sobha Sivaprasad; Philip G Hykin
Journal:  Eye (Lond)       Date:  2021-05-25       Impact factor: 4.456

Review 6.  Recent advances in understanding and managing retinal vein occlusions.

Authors:  Daniel D Esmaili; David S Boyer
Journal:  F1000Res       Date:  2018-04-16

7.  β‑elemene inhibits oxygen‑induced retinal neovascularization via promoting miR‑27a and reducing VEGF expression.

Authors:  Weilai Zhang; Lei Chen; Jin Geng; Limin Liu; Li Xu
Journal:  Mol Med Rep       Date:  2019-01-15       Impact factor: 3.423

Review 8.  Ultra-widefield retinal imaging: an update on recent advances.

Authors:  Samir N Patel; Angell Shi; Turner D Wibbelsman; Michael A Klufas
Journal:  Ther Adv Ophthalmol       Date:  2020-01-20

9.  Repeatability and Reproducibility of Total Retinal Blood Flow Measurements Using Bi-Directional Doppler OCT.

Authors:  Stephan Szegedi; Nikolaus Hommer; Martin Kallab; Stefan Puchner; Doreen Schmidl; René M Werkmeister; Gerhard Garhöfer; Leopold Schmetterer
Journal:  Transl Vis Sci Technol       Date:  2020-06-25       Impact factor: 3.283

10.  Mechanistic Evaluation of Panretinal Photocoagulation Versus Aflibercept in Proliferative Diabetic Retinopathy: CLARITY Substudy.

Authors:  Luke Nicholson; Roxanne Crosby-Nwaobi; Joana C Vasconcelos; A Toby Prevost; Jayashree Ramu; Amy Riddell; James W Bainbridge; Philip G Hykin; Sobha Sivaprasad
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-08-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.